Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire Fosrenol shown effective in six year test

Shire Fosrenol shown effective in six year test

15th November 2005

New six year data presented at the annual meeting of the American Society of Nephrology (ASN) has shown that non-calcium Fosrenol (lanthanum carbonate) can sustain reduced serum phosphorus levels safely in end stage renal disease.

“These study results provide strong evidence of the safety and efficacy of Fosrenol,” said Dr. Alastair Hutchison of the Manchester Institute of Nephrology & Transplantation, one of the trial’s lead investigators,

“With a robust long-term safety profile, ESRD patients and physicians can rely on Fosrenol to help manage hyperphosphatemia and meet Kidney Disease Outcomes Quality Initiative guidelines (K/DOQI),” he added

The open label study examined 93 patients, 32 of whom were treated with Fosrenol for up to six years. The number of treatment related adverse side effects through the study remained consistent while exposure to the drug increased, with gastrointestinal effects the most commonly cited issue.

Crucially, the Fosrenol treated patients also demonstrated reduced serum phosphorus and calcium phosphorus, remaining well within the K/DOQI guidelines.

“Shire is very pleased with the presentation at ASN of these in-vitro and clinical data,” said Dr. Raymond Pratt, vice president Shire Global Clinical Medicine. “Fosrenol is currently available in the US and will be launched across Europe over the coming months.

“Shire is very proud to be able to provide a calcium-free alternative to patients in need of an effective and well-tolerated phosphate binder,” he added.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.